These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 18191614)
1. High prevalence of HCV in a cohort of injectors on methadone substitution treatment. Lee KC; Lim WW; Lee SS J Clin Virol; 2008 Apr; 41(4):297-300. PubMed ID: 18191614 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of hepatitis C infection in injecting drug users in Zadar County, Croatia. Medić A; Dzelalija B; Sonicki Z; Zekanović D Coll Antropol; 2008 Sep; 32(3):697-702. PubMed ID: 18982740 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. Robinson GM; Reynolds JN; Robinson BJ N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873 [TBL] [Abstract][Full Text] [Related]
6. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555 [TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888 [TBL] [Abstract][Full Text] [Related]
8. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Vicknasingam B; Narayanan S; Navaratnam V Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801 [TBL] [Abstract][Full Text] [Related]
9. A multilevel approach for assessing the variability of hepatitis C prevalence in injection drug users by their gathering places. Wong NS; Chan PC; Lee SS; Lee SL; Lee CK Int J Infect Dis; 2013 Mar; 17(3):e193-8. PubMed ID: 23165126 [TBL] [Abstract][Full Text] [Related]
10. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users. Burt RD; Thiede H; Hagan H Drug Alcohol Depend; 2009 Dec; 105(3):215-20. PubMed ID: 19720473 [TBL] [Abstract][Full Text] [Related]
11. The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong. Chan DP; Lee SS; Lee KC J Med Virol; 2011 Jul; 83(7):1187-94. PubMed ID: 21567422 [TBL] [Abstract][Full Text] [Related]
12. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668 [TBL] [Abstract][Full Text] [Related]
13. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M; Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors. Badridze N; Chkhartishvili N; Abutidze A; Gatserelia L; Sharvadze L Georgian Med News; 2008 Dec; (165):54-60. PubMed ID: 19124918 [TBL] [Abstract][Full Text] [Related]
16. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Hickman M; Hope V; Brady T; Madden P; Jones S; Honor S; Holloway G; Ncube F; Parry J J Viral Hepat; 2007 Sep; 14(9):645-52. PubMed ID: 17697017 [TBL] [Abstract][Full Text] [Related]
18. [Risk factors for hepatitis C among injecting drug users in Oslo]. Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801 [TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore. Winslow M; Subramaniam M; Ng WL; Lee A; Song G; Chan YH Singapore Med J; 2007 Jun; 48(6):504-8. PubMed ID: 17538746 [TBL] [Abstract][Full Text] [Related]
20. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Liu JY; Lin HH; Liu YC; Lee SS; Chen YL; Hung CC; Ko WC; Huang CK; Lai CH; Chen YS; Shih YL; Chung HC; Liang SH; Lin JN Clin Infect Dis; 2008 Jun; 46(11):1761-8. PubMed ID: 18433337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]